The key is a thoughtful transition that prioritizes gradual dosing, symptom monitoring, and individualized care
Patients should never self-adjust their dose without explicit guidance from their prescribing physician
Similar content being viewed by others Subjects Introduction Obesity affects more than one-third of individuals in the world, creating an enormous health and economic burden, yet effective non-invasive treatments are limited 1,2
Suspected reactions to unlicensed, falsified or uncertain products can and should be reported at yellowcard.mhra.gov.uk
However, given that GLP-1 drugs are currently not covered by Medicare or Medicaidor most private insurancethe announcement from Trump represents a big change in how the federal government sees these obesity treatments
Nevertheless, action is being taken to dampen the thriving shadow market